In a significant development for Alvotech (NASDAQ: NASDAQ:ALVO ), a global biotech company specializing in biosimilar medicines, the conclusion of the U.S. Food and Drug Administration (FDA) reinspection of its facility in Iceland has brought the company one step closer to achieving regulatory approval for its biosimilar candidates, AVT02 and AVT04. The...
